Business, energy, technology, markets and global industry news from Business News Today

Pharma & Biotech

PharmaDeviceNews Pharma & Biotech
CSL’s positive Phase 3b ANDEMBRY results support planned regulatory filings for garadacimab-gxii in children aged 2 to 11 with hereditary angioedema. Representative image.
Pharma & Biotech

CSL plans expanded pediatric ANDEMBRY filing after positive garadacimab Phase 3b data

CSL’s pediatric ANDEMBRY data support filings in children aged 2 to 11, but regulators still need full safety, PK and efficacy results.

Read More
BioMarin and n-Lorem Foundation are advancing early research into a potential antisense medicine targeting the RNU4-2 variant associated with ReNU syndrome, a newly identified rare neurodevelopmental disorder. Representative image.
Pharma & Biotech

How BioMarin and n-Lorem plan to develop an antisense therapy for ReNU syndrome

BioMarin and n-Lorem launch a preclinical antisense program targeting the RNU4-2 variant behind most ReNU syndrome cases.

Read More
DifGen Pharmaceuticals’ investigational DFGN-101 programme is advancing toward clinical testing as a potential single-injection treatment approach for women with advanced or metastatic breast cancer. Representative image.
Pharma & Biotech

Can one injection replace two? DifGen’s DFGN-101 enters clinical development through a streamlined FDA pathway

DifGen’s DFGN-101 can enter clinical testing after FDA IND clearance, advancing a single-injection approach for advanced breast cancer.

Read More
Cognizin citicoline is being studied for its potential effects on neuromuscular junction formation and nerve-to-muscle signalling, as new preclinical research explores possible applications in healthy ageing and sports nutrition. Representative image.
Pharma & Biotech

Cognizin citicoline enters neuromuscular research as Kirin reports early cell-model findings

Kirin’s Cognizin citicoline improved neuromuscular junction markers in cell models, opening a new research path that still needs human trials.

Read More
Insilico Medicine’s ISM6331 Phase 1 study is evaluating an oral pan-TEAD inhibitor in patients with mesothelioma and other advanced solid tumors ahead of its ESMO 2026 presentation. Representative image.
Pharma & Biotech

What will Insilico Medicine reveal about ISM6331 at the ESMO 2026 Congress?

Insilico Medicine’s first human data for ISM6331 will arrive as clinical interest in TEAD inhibition is accelerating. The presentation must show whether the AI-designed molecule can combine credible antitumor activity with a dose and safety profile suitable for further development.

Read More
A clinician discusses gastroesophageal cancer diagnosis, biomarker testing, treatment options and clinical trials with patients and caregivers ahead of the Debbie’s Dream Foundation and Yale Cancer Center community symposium. Representative image.
Pharma & Biotech

Debbie’s Dream Foundation expands patient education through Yale Cancer Center collaboration

Yale and Debbie’s Dream Foundation will explain diagnosis, biomarkers, treatment, trials and supportive care at a free cancer symposium.

Read More
LAPIX Therapeutics strengthens its strategic leadership by appointing Nimbus Therapeutics Chief Executive Officer Abbas Kazimi to its board as investigational autoimmune drug LPX-TI641 advances through Phase 1b development. Representative image.
Pharma & Biotech

LAPIX Therapeutics adds biotech dealmaking expertise as LPX-TI641 studies progress

LAPIX adds Nimbus CEO Abbas Kazimi to its board as LPX-TI641 advances in Phase 1b autoimmune trials and prepares for Phase 2 decisions.

Read More
Rising GLP-1 drug spending, hospital inflation, artificial intelligence-assisted medical coding and surprise billing arbitration are expected to push employer health plan costs toward a 15-year high in 2027. Representative image.
Pharma & Biotech

What Segal’s 2027 healthcare cost forecast means for employers, payers and PBMs

Segal projects a 9.9% medical plan cost trend for 2027 as GLP-1 drugs, AI coding and arbitration intensify employer cost pressure.

Read More
AstraZeneca’s investigational CLDN18.2 antibody-drug conjugate sonesitatug vedotin improved overall survival in a Phase 3 trial involving previously treated advanced gastric and gastroesophageal junction cancers, although the progression-free survival endpoint was not statistically significant. Representative image.
Pharma & Biotech

Sonesitatug vedotin Phase 3 survival win strengthens AstraZeneca’s gastric cancer ADC strategy

Read why AstraZeneca’s sonesitatug vedotin survival win in CLDN18.2-positive gastric cancer is tempered by a Phase 3 PFS miss.

Read More
Johnson & Johnson’s proposed $5.5 billion settlement aims to resolve about 76,000 existing ovarian talc litigation claims, subject to the required claimant participation. Representative image.
Pharma & Biotech

Could Johnson & Johnson’s $5.5bn talc deal finally close a 15-year legal overhang?

Johnson & Johnson proposes a $5.5 billion deal for 76,000 ovarian talc claims, but participation, future lawsuits and costs remain critical.

Read More